SLOUGH, United Kingdom and
RICHMOND, Va., Nov. 1, 2018
/PRNewswire/ -- Indivior PLC (LON: INDV) today announced that
its financial results for the period ended September 30, 2018, including the earnings
release and investor supplement, are available on the Company's
website at www.indivior.com.
- The earnings press release can be found at
http://www.indivior.com/press-releases/
- The investor supplement can be found at
http://www.indivior.com/news-type/webcasts-audiocasts-presentations/
Indivior will also host a conference call to discuss its
results. The webcast event will be available on the "Investors"
section of the company's website at www.indivior.com. The webcast
link is https://edge.media-server.com/m6/p/bqwwyn7f.
Participants also may access the results presentation
telephonically: US participants +1-929-477-0324; international
participants +44(0)330-336-9105. Please reference confirmation
number 4593067. A replay of the presentation will be available at
www.indivior.com.
About Indivior
Indivior is a global specialty
pharmaceutical company with a 20-year legacy of leadership in
patient advocacy and health policy while providing education on
evidence-based treatment models that have revolutionized modern
addiction treatment. The name is the fusion of the words individual
and endeavour, and the tagline "Focus on you" makes the Company's
commitment clear. Indivior is dedicated to transforming addiction
from a global human crisis to a recognized and treated chronic
disease. Building on its global portfolio of opioid dependence
treatments, Indivior has a strong pipeline of product candidates
designed to both expand on its heritage in this category and
address other chronic conditions and co-occurring disorders of
addiction, including alcohol use disorder and schizophrenia.
Headquartered in the United States
in Richmond, VA, Indivior employs
more than 900 individuals globally and its portfolio of products is
available in over 40 countries worldwide. Visit www.indivior.com to
learn more.
Forward-Looking Statements
This announcement contains
certain statements that are forward-looking and which should be
considered, amongst other statutory provisions, in light of the
safe harbor provisions of the United States Private Securities
Litigation Reform Act of 1995. By their nature, forward-looking
statements involve risk and uncertainty as they relate to events or
circumstances that may or may not occur in the future. Actual
results may differ materially from those expressed or implied in
such statements because they relate to future events.
Forward-looking statements include, among other things, statements
regarding the Indivior Group's financial guidance for 2018 and its
medium- and long-term growth outlook, its operational goals, its
product development pipeline and statements regarding ongoing
litigation.
Various factors may cause differences between Indivior's
expectations and actual results, including: factors affecting sales
of Indivior Group's products; the outcome of research and
development activities; decisions by regulatory authorities
regarding the Indivior Group's drug applications; the speed with
which regulatory authorizations, pricing approvals and product
launches may be achieved; the outcome of post-approval clinical
trials; competitive developments; difficulties or delays in
manufacturing; the impact of existing and future legislation and
regulatory provisions on product exclusivity; trends toward managed
care and healthcare cost containment; legislation or regulatory
action affecting pharmaceutical product pricing, reimbursement or
access; claims and concerns that may arise regarding the safety or
efficacy of the Indivior Group's products and product candidates;
risks related to legal proceedings, including the ongoing
investigative and antitrust litigation matters; the Indivior
Group's ability to protect its patents and other intellectual
property; the outcome of patent infringement litigation relating to
Indivior Group's products, including the ongoing ANDA lawsuits;
changes in governmental laws and regulations; issues related to the
outsourcing of certain operational and staff functions to third
parties; uncertainties related to general economic, political,
business, industry, regulatory and market conditions; and the
impact of acquisitions, divestitures, restructurings, internal
reorganizations, product recalls and withdrawals and other unusual
items.
Corporate Website www.indivior.com
This announcement does not constitute an offer to sell, or the
solicitation of an offer to subscribe for or otherwise acquire or
dispose of shares in the Company to any person in any jurisdiction
to whom it is unlawful to make such offer or solicitation.
View original
content:http://www.prnewswire.com/news-releases/indivior-announces-nine-month-and-third-quarter-2018-results-300742125.html
SOURCE Indivior PLC